Recent studies have demonstrated that lipid-conjugated siRNAs engineered for optimal in situ binding to serum albumin exhibit dramatically enhanced pharmacokinetics and tumor accumulation, with up to 12-fold increased delivery to orthotopic TNBC tumors compared with unconjugated siRNAs. Here, ALB is linked to neoplasm.